Uncategorized

Chris Weihl, MD, PhD New genetic testing technologies are improving the diagnostic journey for many people with neuromuscular diseases. Now, doctors can test 100 or more genes simultaneously when they suspect a patient may have a muscular dystrophy or other inherited neuromuscular disorder. According to Chris Weihl, MD, PhD, a neurologist and Director of the…

Know More

Roche has decided to stop recruitment for their Phase 2 SHIELD DMD study of satralizumab in Duchenne, citing the decision was not due to any new efficacy or safety issues, but rather due to feasibility concerns with meeting regulatory requirements, as well as recruitment and study completion deadlines.  Please see the community letter for more information, including next steps for…

Know More

As a caregiver to three sons living with Duchenne muscular dystrophy (DMD) and a mother to four other children, I have learned a lot over the years. Today, I want to use that knowledge and experience to give back to the community. Being a part of the Duchenne community has been like a buoy to…

Know More

We are disappointed to learn the news that Roche has made the difficult decision to terminate their Phase 2 SHIELD DMD study evaluating satralizumab for bone health in Duchenne.  According to Roche, this decision was reached after careful consideration of the program’s path forward and reflects a combination of factors, including study timelines and the…

Know More

Four people with oculopharyngeal muscular dystrophy (OPMD), a disease type marked by swallowing difficulties, experienced long-lasting improvements in their ability to swallow after receiving the gene therapy candidate BB-301 in an ongoing clinical trial. That’s according to an update from therapy developer Benitec Biopharma, which announced new data from the small trial (NCT06185673), which is…

Know More

Charlotte is 11 years old and lives with LGMD2C, which was diagnosed when she was two and a half. When she grows up, Charlotte wants to get a law degree and become President so that she can make sure rare disease research is funded. Her biggest hope in life is that rare diseases are prioritized,…

Know More

On Jan. 31, I visited the former Supreme Court Foyer at the National Gallery Singapore (NGS) for the final Artsplaining session of Light to Night Singapore 2026. NGS is a leading visual arts museum with the largest collection of Southeast Asian modern art. Artsplaining is its program designed to make the arts accessible to everyone.…

Know More

As an early funder of Entrada Therapeutics, CureDuchenne is pleased to share that after the independent Data Monitoring Committee reviewed the safety data from Cohort 1 of the ELEVATE-44-201 trial in individuals with Duchenne amenable to skipping exon 44, Entrada received recommendation to initiate the higher dose Cohort 2 at 12 mg/kg.  Entrada expects to…

Know More

Dosing has begun in a Phase 2 clinical trial testing the oral therapy SAT-3247 in boys with Duchenne muscular dystrophy (DMD). The study, dubbed BASECAMP (NCT07287189), aims to enroll 51 boys with DMD aged 7-9 who can walk. Patients who have received treatments such as exon skippers, corticosteroids, Duvyzat (givinostat), and Elevidys (delandistrogene moxeparvovec-rokl) may be…

Know More

The 2026 MDA Clinical & Scientific Conference is quickly approaching. Taking place March 8-11, 2026, at the Hilton Orlando in Orlando Florida, this year’s conference will explore the latest research and clinical advancements for neuromuscular disease. In an era of new treatments and life-changing discoveries, this gathering of leading clinicians, researchers, industry partners, advocacy organizations…

Know More